Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Genome-wide association s… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder

Artikel i vetenskaplig tidskrift
Författare J. Song
S. E. Bergen
A. Di Florio
R. Karlsson
A. Charney
D. M. Ruderfer
E. A. Stahl
K. D. Chambert
J. L. Moran
K. Gordon-Smith
L. Forty
E. K. Green
I. Jones
L. Jones
E. M. Scolnick
P. Sklar
J. W. Smoller
P. Lichtenstein
C. Hultman
N. Craddock
Mikael Landén
Publicerad i Molecular Psychiatry
Volym 21
Nummer/häfte 9
Sidor 1290-1297
ISSN 1359-4184
Publiceringsår 2016
Publicerad vid Institutionen för neurovetenskap och fysiologi
Sidor 1290-1297
Språk en
Länkar dx.doi.org/10.1038/mp.2015.165
Ämnesord receptor potential channels, neurotrophic factor gene, prophylactic, lithium, maintenance treatment, japanese patients, trpc5 channels, brain, mechanism, polymorphism, schizophrenia, Biochemistry & Molecular Biology, Neurosciences & Neurology, Psychiatry
Ämneskategorier Psykiatri

Sammanfattning

Lithium is the mainstay prophylactic treatment for bipolar disorder (BD), but treatment response varies considerably across individuals. Patients who respond well to lithium treatment might represent a relatively homogeneous subtype of this genetically and phenotypically diverse disorder. Here, we performed genome-wide association studies (GWAS) to identify (i) specific genetic variations influencing lithium response and (ii) genetic variants associated with risk for lithium-responsive BD. Patients with BD and controls were recruited from Sweden and the United Kingdom. GWAS were performed on 2698 patients with subjectively defined (self-reported) lithium response and 1176 patients with objectively defined (clinically documented) lithium response. We next conducted GWAS comparing lithium responders with healthy controls (1639 subjective responders and 8899 controls; 323 objective responders and 6684 controls). Meta-analyses of Swedish and UK results revealed no significant associations with lithium response within the bipolar subjects. However, when comparing lithium-responsive patients with controls, two imputed markers attained genome-wide significant associations, among which one was validated in confirmatory genotyping (rs116323614, P = 2.74 x 10(-8)). It is an intronic single-nucleotide polymorphism (SNP) on chromosome 2q31.2 in the gene SEC14 and spectrin domains 1 (SESTD1), which encodes a protein involved in regulation of phospholipids. Phospholipids have been strongly implicated as lithium treatment targets. Furthermore, we estimated the proportion of variance for lithium-responsive BD explained by common variants ('SNP heritability') as 0.25 and 0.29 using two definitions of lithium response. Our results revealed a genetic variant in SESTD1 associated with risk for lithium-responsive BD, suggesting that the understanding of BD etiology could be furthered by focusing on this subtype of BD.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?

Denna text är utskriven från följande webbsida:
http://www.gu.se/forskning/publikation/?publicationId=243161
Utskriftsdatum: 2019-10-14